Using patient-reported outcome measures to deliver enhanced supportive care to people with lung cancer: feasibility and acceptability of a nurse-led consultation model by Kotronoulas, Grigorios et al.
 
 
 
 
 
 
Kotronoulas, G., Papadopoulou, C., Simpson, M. F., McPhelim, J., Mack, 
L. and Maguire, R. (2018) Using patient-reported outcome measures to 
deliver enhanced supportive care to people with lung cancer: feasibility and 
acceptability of a nurse-led consultation model. Supportive Care in Cancer, 
26, 3729. (doi:10.1007/s00520-018-4234-x). 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/163211/    
                    
 
 
 
 
 
 
Deposited on: 18 June 2018 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
  
1 
 
TITLE PAGE 
 
Complete Manuscript Title: 
Using patient-reported outcome measures to deliver enhanced supportive care to people with lung 
cancer: Feasibility and acceptability of a nurse-led consultation model 
 
Authors: 
Grigorios Kotronoulas1, PhD, MSc, BSN, RN 
Constantina Papadopoulou2, PhD, MSc, BSN, RN 
Mhairi F. Simpson3, MN, BSc, RN 
John McPhelim3, BSc Hon, RGN 
Lynn Mack3, PGD, RGN 
Roma Maguire4, PhD, MSc, BN, RGN 
 
Author affiliations: 
1Nursing and Health Care, School of Medicine, Dentistry and Nursing, MVLS, University of Glasgow, 
Glasgow, United Kingdom 
2School of Health, Nursing and Midwifery, University of the West of Scotland, Paisley, Glasgow, United 
Kingdom  
3 NHS Lanarkshire, Scotland, United Kingdom 
4Department of Computer and Information Sciences, Digital Health and Wellbeing Group, University of 
Strathclyde, Glasgow, United Kingdom 
 
Corresponding author: 
Dr Grigorios Kotronoulas, Nursing and Health Care, School of Medicine, Dentistry and Nursing, MVLS, 
University of Glasgow; 57-61 Oakfield Avenue, Glasgow, G12 8LL, United Kingdom 
E-mail: grigorios.kotronoulas@glasgow.ac.uk; Tel: +44 (0) 141 330 6883 
 
Disclosures: 
The present work was supported through a grant awarded by NHS Lanarkshire. The views presented 
in this article are those of the authors not of the funding body. 
 
Conflict of interest statement: 
The authors declare that they have no personal or financial conflicts of interest to disclose. 
 
 
 
 
  
2 
 
ABSTRACT 
 
Purpose: Developing new supportive/palliative care services for lung cancer should encompass 
effective ways to promptly identify and address patients’ healthcare needs. We examined whether an 
in-clinic, nurse-led consultation model, which was driven by use of a patient-reported outcomes (PRO) 
measure, was feasible and acceptable in the identification of unmet needs in patients with lung cancer. 
 
Methods: A two-part, repeated-measures, mixed-methods study was conducted. Part 1 employed 
literature reviews and stakeholder focus group interviews to inform selection of a population-appropriate 
needs assessment PRO measure. In Part 2, lung cancer nurse specialists (CNS) conducted three 
consecutive monthly consultations with patients. Recruitment/retention data, PRO data, and exit 
interview data were analysed. 
 
Results: The Sheffield Profile for Assessment and Referral to Care was the PRO measure selected 
based on Part 1 data. Twenty patients (response rate: 26%) participated in Part 2; 13 (65%) participated 
in all three consultations/assessments. The PRO measure helped patients to structure their thinking 
and prompted them to discuss previously underreported and/or sensitive issues, including such topics 
as family concerns, or death and dying. Lung CNS highlighted how PRO-measures-driven consultations 
differed from previous ones, in that their scope was broadened to allow nurses to offer personalised 
care. Small-to-moderate reductions in all domains of need were noted over time.  
 
Conclusions: Nurse-led PRO-measures-driven consultations are acceptable and conditionally feasible 
to holistically identify and effectively manage patient needs in modern lung cancer care. PRO data 
should be systematically collected and audited to assist in the provision of supportive care to people 
with lung cancer. 
 
 
Keywords: Lung cancer; Needs assessment; Unmet needs; Patient-reported outcome (PRO) 
measures; Nurse specialist; Supportive care 
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Background 
Lung cancer remains the most common cause of cancer-related death, accounting for approximately 
20% of the total cancer mortality [1]. In spite of recent treatment advances, survival rates remain poor 
[2]. The majority of patients still present with advanced disease, at a stage where use of treatment with 
curative intent is limited [3]. Not only people with lung cancer are physically challenged, but also they 
have unmet healthcare needs, in many cases significantly more when compared to people with other 
cancer types [4]. Early and effective supportive and palliative care is therefore paramount in this patient 
group [4–6]. Supportive and palliative care ‘helps the patient to maximise the benefits of treatment and 
to live as well as possible with the effects of the disease’  and should ‘be given equal priority with other 
aspects of care’ [7, 8]. 
 
The development and integration of new supportive/palliative care services should encompass 
innovative ways to promptly identify the healthcare needs of people with lung cancer. Using patient-
reported outcome (PRO) measures in routine cancer care practice can be beneficial to this effect [9, 
10]. PRO measures are defined as ‘measurements of an aspect of a patient’s health status that come 
directly from the patient’ [11]. Deriving data (referred to as ‘PRO data’) can be used to alert clinicians 
on emerging and priority needs and concerns, enable active clinician review of the patient’s health 
status towards prompt clinical intervention. There is now mounting research evidence that collection of 
PRO data that is followed by a tailored clinical response can lead to improved patient-clinician 
communication, better symptom control, increased use of supportive care measures, improvements in 
self-efficacy, patient satisfaction with cancer care, and survival [10, 12–14].  
 
Despite positive evidence, implementation of PRO-measures-driven consultation models in routine 
clinical practice has been challenging and not fully realised [15]; lung cancer care is not an exception. 
One reason is that, for such a complex healthcare intervention to be successfully implemented, careful 
research planning and design is required to deploy key components, identify resultant effects of PRO 
data collection and use, and tackle any barriers to inform future policy and practice [10, 12, 16]. Drawing 
on this gap in current literature, we aimed to develop a nurse-led, PRO-measures-driven consultation 
model (intervention) to enhance the delivery of supportive/palliative care to people with lung cancer, 
and test its feasibility and acceptability in routine clinical practice. Secondarily, we examined the 
prevalence, intensity and over-time change in reported supportive care needs in the study sample as a 
preliminary indication of intervention-related effects. We selected a nurse-led model because, among 
members of the multidisciplinary team, nurses are consistently seen as being the most appropriate 
practitioners to lead on PRO measure use [17]. Indeed, current evidence supports lung cancer nurse 
specialists (CNS) as providers of tailored care that is likely to improve patient symptom control, reduce 
unnecessary hospital admissions, and increase satisfaction with care [5, 18, 19]. 
 
 
Methods 
This was a two-part, mixed-methods study, with each part designed to contribute to achieving the overall 
study aim. The study was informed by the Medical Research Council (MRC) complex interventions 
framework [20] referring to the feasibility/pilot and developmental elements of the framework. Ethical 
approval was granted by the local Research Ethics Committee.  
 
Part 1: Intervention development stage 
In Part 1, we generated research evidence to assist us on refining aspects of the intervention and 
selecting the most appropriate needs assessment PRO measure for use in Part 2. First, we reviewed 
the relevant literature. We conducted one systematic review on patients’ supportive care needs, and 
one on available needs assessment PRO measures. Methodological details of these reviews have been 
published elsewhere [21, 22]. We shortlisted PRO measures based on key parameters, including target 
population and setting; content, length, comprehensiveness and representativeness; scoring; 
psychometric properties (validity, reliability, responsiveness to change); feasibility (time, reading level); 
and respondent acceptability (length, wording). Subsequently, we scoped out the views and opinions 
of people with lung cancer and health professionals on important aspects of supportive care for this 
patient group. For this exercise, we conducted two focus group interviews, one with patients and one 
with health professionals, using a purposive sampling procedure at one NHS board in the UK. Eligible 
patients were (a) diagnosed with lung cancer; (b) at different phases of the cancer trajectory; (c) deemed 
physically and psychologically fit to participate; (c) able to read and write English; (d) able to provide 
written informed consent; (e) aged ≥18 years; and (f) able to provide consent for the researcher to 
access hospital case notes. Eligible health professionals were lung CNS registered within the 
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participating health board. During the focus group sessions, all participants were asked to provide basic 
demographic information on an author-developed form. Patient clinical data were collected from 
hospital case notes. At the end of each focus group, we involved participants in a 10-minute exercise, 
whereby shortlisted PRO measures were distributed to each group. Participants reviewed the PRO 
measures and selected the three ‘most appropriate’ for use in lung cancer care, in terms of overall 
presentation, length, wording, and comprehensiveness. 
 
Part 2: Feasibility testing stage 
In Part 2, we conducted a single-arm, repeated measures trial to test the feasibility and acceptability of 
the consultation model (intervention), whereby the lung CNS used the selected needs assessment PRO 
measure during clinical consultations to identify patients’ priority healthcare needs and provide tailored 
care. As per guidance for early feasibility testing [23, 24], we aimed to recruit up to 30 patients with lung 
cancer from the same health board. None of the Part 1 patients was involved in Part 2. Patient eligibility 
criteria were as follows: (a) histologically confirmed diagnosis of lung cancer; (b) life expectancy ≥4 
months; (c) deemed physically and psychologically fit to participate; (d) able to read and write English; 
(e) able to provide written informed consent; and (f) able to provide consent for the researcher to access 
hospital case notes. Lung CNS participants were the same individuals as in Part 1. 
 
Three consecutive patient-clinician consultations took place at monthly intervals, i.e. baseline (T1); 1 
month post-baseline (T2); and 2 months post-baseline (T3). This approach acknowledged the limited 
survival of this patient group [25], thus allowing sufficient time to pilot-test with reduced risk for death-
related attrition. At each time-point, patients completed the selected PRO measure in a quiet room in 
the hospital immediately prior to their appointment with the lung CNS. Subsequently, the lung CNS met 
with the patient and used PRO data to identify unmet needs, direct discussions, and intervene 
accordingly. The lung CNS documented any identified needs and clinical interventions/advice in author-
developed pro-formas. No specific clinical guidance was given to lung CNS as to how to respond to 
patient needs.  
 
To assess intervention feasibility we analysed data on patient availability/recruitment, time and resource 
requirements, missing data, and patient retention. In terms of acceptability, we investigated patient 
adherence to the intervention, perceived burden, value and appropriateness of the timing of delivery. 
At the end of the study, we conducted exit interviews with a subset of patients (n≤10) and the lung CNS 
to explore their perceptions on the tested intervention in greater depth, and gather suggestions for 
improvement. Secondarily, we analysed PRO measure data to explore the prevalence of supportive 
care needs in the study sample, and how and in what extent these needs changed from T1 to T3. 
 
Data Analysis 
All interviews (Parts 1 and 2) were aided by the use of topic guides that employed open-ended 
questions, and were audio recorded and transcribed verbatim. The software analysis package QSR 
NVivo© was used to aid organisation of the data that was classified into themed categories. Analysis 
of the data was thematic, focussing on whether and how participants agreed or disagreed about each 
issue [26]. For reliability and validity purposes, two researchers coded interviews separately and then 
cross-checked them. 
 
Quantitative data (Part 2) were analysed using SPSS (IBM SPSS Inc.; Chicago, IL) descriptive statistics 
functionality and graphs. The dataset was checked for missing values, and these was approximated 
accordingly. Frequency counts for each item on the PRO measure were generated to describe response 
patterns. Individual items were also aggregated to yield scores on domains of need. To assess 
sensitivity to change, effect sizes were calculated for individual items, and effect sizes and standardised 
response means (SRM) for all of the domains of need [27, 28]. Effect sizes and SRM of 0.2, 0.5 and 
0.8 were regarded as indicating small, moderate and large degrees of change, respectively [29]. 
Friedman tests with post hoc between groups comparisons (Mann-Whitney U) were used to test for 
significant over-time changes in the domain of need scores. All tests were two-sided; the level of 
significance was set at 0.05.  
 
 
Results 
Part 1 
Our systematic reviews identified a wide range of unmet needs in people with lung cancer [22], and 
generated a pool of twenty-six validated, self-report PRO measures to assess these needs [21]. We 
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specifically targeted PRO measures that assessed the majority of identified domains of need, i.e. 
physical (loss of energy, breathlessness, pain, sleeplessness); psychological (anxiety, loss of control, 
sadness, feeling a burden); social (impact of illness on family members); daily living (not being able to 
work/do housework); practical (too much time wasted over diagnosis/treatment); communication 
(having a clinician to trust and available); information (things one could do to help get well); and spiritual 
needs (fear of the unknown) [22]. As such, we shortlisted eleven PRO measures, which we introduced 
to focus group participants. During the focus groups, patients (n=4; three men) confirmed their living 
with multiple needs, particularly stressing the importance of receiving help with their practical and daily 
living needs. The lung CNS (n=3; two women; all >6 years clinical experience in lung cancer care) noted 
how patients’ needs are “…interlinked and of equal importance” (CNS1), but acknowledged that the 
complexity of lung cancer care often rendered needs assessments challenging. Based on these views, 
focus group participants agreed that the Sheffield Profile for Assessment and Referral to Care (SPARC) 
[30] was the most appropriate/suitable PRO measure, which was seen as “brief, comprehensive, and 
to the point” (CNS2). The SPARC consists of 45 items that concern communication and information 
issues, physical symptoms, psychological issues, religious and spiritual issues, independence and 
activity, family and social issues, treatment and person issues. Recent research supports its 
psychometric properties and acceptability among patients with thoracic cancer [31]. 
 
Part 2 
Feasibility: Recruitment/refusal Rates 
From February 2011 to April 2012, 76 eligible patients were identified; 56 refused for various reasons. 
These included starting treatment and wanting to focus on that (n=5); concurrent participation in another 
clinical trial (n=3); too unwell (n=7); just out of hospital (n=2); too much on at the moment (n=26); poor 
concentration (n=2); too many hospital visits (n=4); additional time factor (n=5); transportation and 
relocation issues (n=2). The final sample consisted of 20 patients (response rate 26.3%) who provided 
written informed consent. Patient demographic and clinical characteristics are shown in Table 1.  
 
Feasibility: Patterns of Missing Data and Attrition Rates 
Missing items due to non-response were scarce (<2%) irrespective of assessment point. No specific 
patterns of missing data were observed. From T1 to T2, five patients were lost to follow-up. Reasons 
included deterioration in condition (n=3), decision to withdraw after treatment had stopped due to 
toxicities (n=1), and difficulty to attend consultations (n=1). Two more patients dropped out between T2 
and T3 due to deterioration in their health status. As a result, thirteen patients (attrition rate 35%) 
completed all three assessments.  
 
Perceived acceptability and value of the intervention 
Nine patients with lung cancer (6 men, 3 women) and three lung CNS (2 women, 1 man) took part in 
exit interviews. Two themes were generated, namely “Perceptions regarding the delivery of the 
intervention” and “Reflections on the change in clinical consultations” (Table 3). 
 
 Theme 1: Perceptions regarding the delivery of the intervention 
Patients found the SPARC easy to understand and complete, whilst its scoring system allowed 
them to self-assess how their symptoms and needs changed over time, instilling a sense of 
control (Q1). Patients felt that the SPARC prompted discussion on the full spectrum of their 
potential needs; yet, some suggested the inclusion of additional questions regarding 
psychological issues (Q2, Q3). Having a highly individualised one-to-one session with the lung 
CNS was positively viewed as it created a familiar and safe environment for discussion (Q4). 
Eight patients also agreed that ‘once a month’ was “just right” as this time frame allowed enough 
time for the nurse to implement an intervention and subsequently evaluate if it was working. 
 
Lung CNS perceived that the questionnaire offered an easy format for them to assess patients’ 
priority needs (Q5). It was however highlighted that more junior staff may have not been able 
to deal with the full spectrum of patient needs, especially those more sensitive issues, and that 
formal training in discussing these domains of need is required (Q6). Like patients, the CNS 
viewed the face-to-face aspect of the intervention an important part of the study (Q7). For one 
lung CNS, having PRO data available in advance of the actual consultation appointment was 
perceived to be helpful to give the CNS time to organize resources and appropriate methods of 
management. It was also suggested that for those patients who are unable to attend acute care, 
the SPARC be delivered in the community setting by primary care staff (e.g. District or 
Macmillan nurses) or via home visits by the CNS. The point of diagnosis, end of treatment and 
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follow-up were perceived to be key points of patient need; it was thus suggested that these 
crucial time points be considered in future assessments (Q8, Q9).  
 
 Theme 2: Reflections on the change in clinical consultations 
Patients felt that the intervention provided structure to their thinking, whilst enabled them to be 
active participants in their care. This gave them a sense of empowerment and control (Q10, 
Q11). Patients described how some long-term symptoms, such as breathlessness, had been 
re-assessed and subsequent interventions had led to significant improvements. It appeared 
that these symptoms had been bypassed in previous consultations due to their chronicity or to 
being attributed to other conditions (Q12). All participants commented on how having dedicated 
time with the CNS was unlike their experiences of previous consultations, which were 
predominantly rushed and only focusing on one area of care (Q13). The consistency of meeting 
with the same CNS each time was also viewed positively as it allowed for a rapport to be built, 
making it easier for patients to share their concerns. 
 
Lung CNS highlighted how the consultations appeared to differ from previous ones, in that the 
patients were driving consultations, bringing up issues that were pertinent to them (Q14). This 
approach appeared to lead to a more holistic method of assessment that encompassed many 
domains of the patient experience. Sensitive issues, such as death and dying, concerns 
regarding family, the effects of treatment and sexuality were commonly raised, and these were 
issues that were rarely discussed previously. Reflecting on standard consultations, lung CNS 
acknowledged that previously consultations tended to mainly focus on physical needs. Use of 
the SPARC was perceived to provide patients with an ‘open invitation’ to report a wide array of 
needs; in turn, it provided CNS with a ‘direct invitation’ to even discuss sensitive issues (Q15). 
In addition, the dedicated consultations allowed CNS to spend time with the patient and 
understand the underlying cause of concerns, which in turn resulted in more appropriate 
management (Q16). 
 
Prevalence and Over-Time Change in Reported Needs 
Dealing with physical ailment (predominantly, shortness of breath, cough, fatigue and sleeplessness), 
feeling anxious and in a low mood, and feeling that everything was an effort were predominant sources 
of concern throughout Part 2 (Suppl. Table). Close to 40% reported having worrying thoughts about 
death and dying regardless of time-point. Eight in 10 also reported worrying about the effect their illness 
was having on their family and significant others. 
 
In aggregated analyses (Table 3), a relative reduction in the magnitude of patients’ needs was observed 
from T1 to T2 and from T1 to T3. Change-related effect sizes were predominantly small, except for the 
spiritual needs domain (T1-T2) and the family/social needs and treatment concerns domains (T1-T3). 
Moderate SRMs were also found for the physical and psychological domains of need.  
 
Friedman tests revealed only trends towards reduction in spiritual/religious, family/social and treatment 
concerns across the three time-points (0.10≥p>0.05). A significant reduction in the magnitude of 
psychological and spiritual needs was found from T1 to T2, whilst reductions in family/social and 
treatment concerns from T1 to T3 were also evident (p<0.05). With the exception of the latter domains, 
relapse to baseline levels was observed at T3 for all other domains of need (Figure 1). 
 
 
Discussion 
Our findings suggest that this nurse-led, PRO-measures-driven consultation model is acceptable to 
both patients with lung cancer and lung CNS, and conditionally feasible in clinical practice to enhance 
delivery of supportive/palliative. Our study also highlights the potential for the model to lead to 
meaningful reductions in patients’ unmet needs that could be associated with gains in quality of life. 
Hard evidence on the effects of the routine use of PRO measure feedback on the supportive care needs 
of patients with cancer is scarce [10]. However, the observed significant reduction in the psychological 
and spiritual domains of need (T1 to T2), and family/social and treatment concerns domains (T1 to T3) 
suggest that, despite the lack of a control group, these patient outcomes are amenable to improvement 
in clinical practice [32]. No significant overall change in the physical needs domain was found, thus 
supporting existing evidence suggesting persistent symptom distress for patients with lung cancer over 
time [33]. 
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Whilst small, our study suggests that PRO-measure-driven consultations may act as facilitators to a 
comprehensive assessment that leads to prompt identification and tailored management of needs in 
this patient group. In exit interviews, patients highlighted how the selected PRO measure prompted 
them to think about their full spectrum of needs, resulting in them flagging needs and concerns that they 
would not have been identified previously. Relevant evidence purports the usefulness of PRO measures 
in identifying issues that are most bothersome to patients [34]. Our findings are of particular significance 
as people with lung cancer have been reported to be reluctant to ask for help with their needs [35]. 
Patients also commented positively on the opportunity to establish a close relationship with the CNS 
that contributed to their sense of being cared for. PRO-measures-driven consultations can help 
establish rapport during early palliative care for lung cancer that can act as a means of reassurance for 
patients that their needs and preferences are taken into account [6]. Lung CNS described how patients 
were ‘driving’ the consultations, using the PRO measure to highlight issues that were most important to 
them, and be in control of the flow of information. Often, such issues went beyond physical symptoms, 
i.e. issues about death and dying, or concerns about the family [32]. Evidence suggests that nurses 
perceive physical needs as easier to assess/manage than other needs [36, 37]. Such perceptions may 
lead clinicians to neglect important non-physical needs, unless clinical assessments directly involve the 
patient. PRO-measures-driven consultations serve this very notion. As part of a multidisciplinary team 
effort, referrals would be warranted where necessary (e.g. for patients with complex psychosocial 
needs), but dedicated training programs could be of particular help to increase confidence among lung 
CNS to address less salient (and more sensitive) needs that may be considered ‘challenging’ and 
potentially off-putting. 
 
While attrition rate was kept to a moderate 35% considering a physically challenging illness like lung 
cancer, only about 3 in 10 eligible patients were enrolled in the study in the first place. Whether patient 
access rates would be the same should this model be a fully integrated healthcare service can only be 
assumed. However, patient accessibility to a potentially useful service could be questioned. This is 
particularly relevant for PRO-measures-driven consultation models that claim to promote patient-
centredeness and inclusivity in a highly systematic way [10, 38]. For instance, PRO-measures-driven 
consultation models could enhance patient accessibility to tailored care, particularly in light of reports 
that older patients with poorer performance status, earlier cancer stage, and more comorbidities may 
be less likely to be assessed by a lung CNS [39]. For this to be realised, there is a clear indication for 
further refinement of this service model before implementation takes place. In line with participants’ 
suggestions, a number of steps can be taken to increase operationalisation of the delivery of PRO 
measures-driven needs assessments in this area. Patient self-assessments prior to consultation 
appointments could allow for adequate time for nurses to evaluate patient feedback and organise 
resources according to need priority. Harnessing technology to realise collection of PRO data is a 
crucial step to this direction [40], especially as it can help overcome patient participation barriers that 
can adversely impact on feasibility and deployment of this service. Moreover, ensuring availability of 
such services in the community rather than exclusively in acute care is important to ensure that patients 
cared for at home are not excluded from needs assessments. This is an important component of the 
future delivery of PRO-measures-driven consultation models in light of the advanced nature of lung 
cancer [25] and the shift of services to local settings [41, 42].  
 
A number of limitations warrant commenting. First, representativeness of the study sample is limited to 
older male, married and well-educated patients, with good performance status and a limited number of 
additional co-morbidities. It thus may be argued that our patient group was not representative of the 
general lung cancer population. Second, delivery of in-clinic consultations may have excluded patients, 
who were unable to attend due to practical difficulties or health status. Third, the pre-requisite for 
patients to be able to read and write English may have acted as a barrier to recruitment of non-English 
speaking patients. Similarly, our sample of lung CNS included highly experienced health professionals, 
which questions whether similar findings would have been yielded with less experienced clinicians. 
Finally, the non-experimental nature of this feasibility study precludes safe conclusions on the 
effectiveness of this intervention model. In conjunction with the small sample size, poor response rate, 
and moderate attrition rate, findings should be interpreted with caution. 
 
 
Conclusions 
Nurse-led PRO-measures-driven consultations are acceptable and conditionally feasible to holistically 
identify and effectively manage patient needs in modern lung cancer care. Lung CNS are key 
professionals in the delivery of supportive care, and are receptive to and able to act upon information 
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gleaned from PRO measures in clinical practice. Pragmatic controlled trials are required to demonstrate 
the definitive impact of the delivery of PRO measures on lung cancer patient outcomes, at the same 
time taking into consideration the expectations of end users and the challenges of clinical practice. 
Whilst key time-points for PRO assessments in lung cancer care seem to be diagnosis and end of 
treatment/follow-up, systematic on-going needs assessments should be pursued throughout the illness 
experience. 
 
  
9 
 
Conflicts of Interest 
The authors declare that there are no financial or other conflicts of interest with regard to this study. 
 
Statement of Authorship 
All authors have equally contributed to the preparation of this manuscript. 
 
Acknowledgments 
We would like to thank all patients for their valuable contribution to this study. 
 
 
  
10 
 
FIGURE AND TABLE LEGENDS 
 
Figure 1. Over-time changes in median scores of the six SPARC domains of need. 
 
Table 1. Baseline demographic and clinical patient characteristics (n=20). 
 
Table 2. Frequency distribution of individual needs and change-related effects sizes. 
 
Table 3. Themes and quotes from exit interviews with patients and lung CNS. 
 
Suppl. Table. Descriptive statistics and effect sizes of the six SPARC domains of need. 
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TABLES 
Table 1. Baseline demographic and clinical patient characteristics (n=20) 
  Frequency % 
Age Mean (SD) 67.1 (8.62)  
Median 69.5  
Range 32 (51-83)  
IQR 13  
Time since diagnosis (days)a Mean (SD) 284.6 (404.3)  
Median 118.0  
Range 1401 (20-1421)  
IQR 267  
Gender Male 13 65.0 
Educational background High school 18 90.0 
Some college 1 5.0 
University 1 5.0 
Marital status Married/partnered 13 65.0 
Single 2 10.0 
Divorced 3 15.0 
Widowed 2 10.0 
Employment status Employed 2 10.0 
Unemployed 4 20.0 
Retired 14 70.0 
Type of disease NSCLC 16 80.0 
SCLC 2 10.0 
Other (e.g. mesothelioma) 2 10.0 
Disease stageb Local 9 47.4 
Metastatic 10 52.6 
Co-morbid illnesses Yes 5 25.0 
an=11 
bn=19 
Abbreviations: IQR – Interquartile range; NSCLC – non-small cell lung cancer; SCLC – small cell lung cancer 
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Table 2. Descriptive statistics and effect sizes of the six SPARC domains of need 
SPARC domain of 
need 
T1 
M±SD 
(range) 
T1 
Median 
(IQR) 
ES 
T1-T2 
ES 
T1-T3 
SRM 
T1-T2 
SRM 
T1-T3 
Physical 17.00±8.83 
(1-42) 
15.00 (10) -0.255 
 
-0.187 
 
-0.447 -0.263 
Psychological/ emotional 4.15±4.57 
(0-20) 
3.00 (4) -0.285 
 
-0.142 
 
-0.504 -0.272 
Spiritual/religious 0.85±0.99 
(0-3) 
0.50 (2) -0.455 
 
0.0 -0.507 0.0 
Independence 1.20±1.91 
(0-7) 
0.00 (3) -0.236 
 
-0.052 
 
-0.306 -0.062 
Family/social 1.65±1.27 
(0-4) 
1.00 (2) -0.236 
 
-0.513 
 
-0.217 -0.549 
Treatment concerns 1.85±1.63 
(0-6) 
2.00 (3) -0.215 
 
-0.521 
 
-0.259 -0.484 
Abbreviations: ES – effect size; SRM – standardised response mean; M – mean; SD – standard deviation; IQR – Interquartile 
range; SPARC – Sheffield Profile for Assessment and Referral to Care. 
Notes: ES are calculated as the difference between a mid-point and baseline score divided by the standard deviation (SD) of 
the baseline scores. SRM are calculated as the ratio of individual change to the SD of that change, after change scores (T2 
minus T1, T3 minus T1) were calculated. Expectation-maximisation imputation was used to replace missing values for domain-
of-need scores at T2 and T3, following a separate analysis to examine the possibility of attrition bias. No significant demographic 
or clinical differences between study completers and non-completers (p>0.05) were found, except for disease stage where non-
completers were at a more advanced stage compared to completers (Z=-2.147; p=0.032). 
Key: Cohen’s d benchmarks d= 0.2 (small effect), 0.5 (moderate effect) and 0.8 (large effect); Key 2: ES of -0.25 indicates 
decrease of 0.25 SD 
 
 
  
15 
 
Table 3. Themes and quotes from exit interviews with patients and lung CNS 
Respondent 
Emerging themes 
#1 Perceptions regarding the delivery of the 
intervention 
#2 Reflections on the change in clinical 
consultations 
Patient quotes Q1: “they [the questions] made you think, like 
I, I'm not as bad as I think I am, you know 
when you see the… the different 
categories and you're saying ‘I'm a 1, or 
I'm a 2, or…’, whatever it's a, well it's really 
it's not that bad and it made me feel better” 
P3. 
Q2: “the only down thing I found that was 
lacking a bit was what’s going on in your b-
r-a-i-n” P3. 
Q3: “I think even if the questionnaire would 
say just plain simple terms, “how did you 
cope with it in your mind?” P8. 
Q4: “…the most useful thing I’ve found is 
actually the one to one…” P9. 
Q10: “eh, the questions made you think 
about what was going on and how your 
body was reacting and made you think 
more about what you wanted” P3. 
Q11: “…It made me feel as if, yeah I was 
achieving something” P1. 
Q12: “…if I had'nae done this, the, I'd ah just 
been going on and on eh with it, and they 
think this is coming from the COPD that I 
have, rather than the cancer, so that’s 
good” P2. 
Q13: “I think I would, now I would ask a lot 
more questions now… Before then I was 
just sitting and it was just… ppfft! – right 
over my head, went over my head and it 
was my wife that was picking, picking it all 
up” P1. 
Lung CNS 
quotes 
Q5: “I suppose I thought it was very clear, I 
thought patients do like the tick box thing… 
and em I think there was a wide variety of 
areas that they could tick” CNS2. 
Q6: “I think a lot of patients like the fact that 
they’ve got the appointment and it’s that 
physical contact that they like with you” 
CNS2. 
Q7: “I’m just talking about having a level of 
experience and eh… and almost I suppose 
some type of post graduate education or 
further education to underpin what they’re 
being asked to do and experiential work as 
well I know that’s absolutely like vital” 
CNS3. 
Q8: “there’s no reason why this cannot be 
built into a patient pathway through the 
diagnostic pathway at the point of 
diagnosis this could be administered to 
patients and at whatever time frame 
people felt was appropriate and beyond 
that” CNS3. 
Q9: “…and then you know once disease 
progresses, I suppose they are on their 
next lot of treatment after that and then 
their moving towards end of life” CNS2. 
Q14: “I think the tool has been a useful…in 
guiding consultations with patients and 
often guiding you to areas of concerns for 
patients that you might otherwise not of 
thought about or not have interrogated as 
rigorously without the tool” CNS3. 
Q15: “I suppose when you have these 
consultations with patients, you are often 
depending on the patient being prepared 
to verbalise what their concerns are or 
being articulate enough to eh express 
them whereas I think you know if say they 
have to sit and they’ve had the opportunity 
to fill the questionnaire in, em… it probably 
gives you a bit better insight into what’s 
going on… in their head… ...for me I think 
for certainly the patients that participated it 
made them open up a wee bit, so in terms 
of it being a positive experience I think I 
probably got more out of the 
consultations…” CNS3. 
Q16: “I mean I just have to emphasise…I 
really liked it…and I thought it was really 
useful and I liked the structure [mmm] of 
the appointments and the fact that you 
could follow interventions through and it’s 
good to see that you’re making a 
difference…” CNS2. 
Abbreviations: CNS – Cancer Nurse Specialist; COPD – Chronic obstructive pulmonary disease. 
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Suppl. Table. Frequency distribution of individual needs and change-related effects sizes 
SPARC T1 (n=20) T2 (n=15) T3 (n=13) 
ES T1-T2 ES T1-T3 Domain 
of need 
Item 0 1 2-3 0 1 2-3 0 1 2-3 
Physical Pain 6 (30.0) 10 (50.0) 4 (20.0) 9 (60.0) 5 (33.3) 1 (6.7) 4 (30.8) 8 (61.5) 1 (7.7) -0.577 -0.250 
Loss of memory 16 (80.0) 3 (15.0) 1 (5.0) 11 (73.3) 4 (26.7) – 11 (84.6) 1 (7.7) 1 (7.7) 0.036 -0.036 
Headache 12 (60.0) 7 (35.0) 1 (5.0) 10 (66.7) 4 (26.7) 1 (6.7) 10 (76.9) 3 (23.1) – -0.082 -0.363 
Dry mouth 3 (15.0) 12 (60.0) 5 (25.0) 5 (33.3) 6 (40.0) 4 (26.7) 1 (7.7) 9 (69.2) 3 (23.1) -0.265 0.078 
Sore mouth 9 (45.0) 5 (25.0) 6 (30.0) 9 (60.0) 5 (33.3) 1 (6.7) 6 (46.2) 4 (30.8) 3 (23.1) -0.400 -0.095 
Shortness of breath 2 (10.0) 9 (45.0) 9 (45.0) 2 (13.3) 7 (46.7) 6 (40.0) 1 (7.7) 3 (23.1) 9 (69.2) -0.201 0.321 
Cough 5 (25.0) 9 (45.0) 6 (30.0) 5 (33.3) 7 (46.7) 3 (20.0) 7 (53.8) 2 (15.4) 4 (30.8) -0.328 -0.348 
Feeling sick (nausea) 10 (50.0) 7 (35.0) 3 (15.0) 9 (60.0) 3 (20.0) 3 (20.0) 9 (69.2) 4 (30.8) – -0.034 -0.451 
Being sick (vomiting) 15 (75.0) 4 (20.0) 1 (5.0) 12 (86.7) 1 (6.7) 1 (6.7) 8 (61.5) 4 (30.8) 1 (7.7) -0.175 0.280 
Bowel problems 10 (50.0) 6 (30.0) 4 (20.0) 8 (53.3) 6 (40.0) 1 (6.7) 5 (38.5) 7 (53.8) 1 (7.7) -0.212 -0.012 
Bladder problems 15 (75.0) 3 (15.0) 2 (10.0) 11 (73.3) 4 (26.7) – 10 (76.9) 2 (15.4) 1 (7.7) -0.190 -0.074 
Feeling weak 5 (25.0) 10 (50.0) 5 (25.0) 3 (20.0) 7 (46.7) 5 (33.3) 6 (46.2) 3 (23.1) 4 (30.8) 0.179 -0.110 
Feeling tired 2 (10.0) 8 (40.0) 10 (50.0) 1 (6.7) 6 (40.0) 8 (53.3) 1 (7.7) 7 (53.8) 5 (38.5) 0.036 -0.048 
Problems sleeping at night 7 (35.0) 5 (30.0) 7 (35.0) 5 (33.3) 5 (33.3) 5 (33.3) 6 (46.2) 3 (23.1) 4 (30.8) 0.029 -0.176 
Feeling sleepy during the day 3 (15.0) 12 (60.0) 5 (25.0) 1 (6.7) 10 (66.7) 4 (26.7) 3 (23.1) 7 (53.8) 3 (23.1) 0.067 -0.201 
Loss of appetite 7 (35.0) 7 (35.0) 6 (30.0) 6 (40.0) 6 (40.0) 3 (20.0) 5 (38.5) 6 (46.2) 2 (15.4) -0.217 -0.250 
Changes in your weight 6 (30.0) 12 (60.0) 2 (10.0) 7 (46.7) 7 (46.7) 1 (6.7) 5 (38.5) 7 (53.8) 1 (7.7) -0.242 -0.215 
Problems with swallowing 15 (75.0) 4 (20.0) 1 (5.0) 12 (80.0) 3 (20.0) – 8 (61.5) 4 (30.8) 1 (7.7) -0.201 0.255 
Concerned about changes in appearance 14 (70.0) 5 (25.0) 1 (5.0) 8 (53.3) 5 (33.3) 2 (13.3) 9 (69.2) 3 (23.1) 1 (7.7) 0.426 0.051 
Feeling restless and agitated 12 (60.0) 6 (30.0) 2 (10.0) 10 (66.7) 3 (20.0) 2 (13.3) 9 (69.2) 2 (15.4) 2 (15.4) -0.024 -0.012 
Feeling that symptoms are not controlled 14 (70.0) 4 (20.0) 2 (10.0) 11 (73.3) 3 (20.0) 1 (6.7) 9 (69.2) 2 (15.4) 2 (15.4) -0.145 0.012 
Psychological Feeling anxious 7 (35.0) 10 (50.0) 3 (15.0) 6 (40.0) 6 (40.0) 3 (20.0) 7 (53.8) 4 (30.8) 2 (15.4) -0.061 -0.283 
Feeling in a low mood 6 (30.0) 9 (45.0) 5 (25.0) 6 (40.0) 5 (33.3) 4 (26.7) 7 (53.8) 4 (30.8) 2 (15.4) -0.081 -0.443 
Feeling confused 17 (85.0) 2 (10.0) 1 (5.0) 14 (93.3) – 1 (6.7) 11 (84.6) 1 (7.7) 1 (7.7) -0.167 -0.028 
Feeling unable to concentrate 14 (70.0) 4 (20.0) 2 (10.0) 12 (80.0) 2 (13.3 1 (6.7) 10 (76.9) 2 (15.4) 1 (7.7) -0.218 -0.169 
Feeling lonely 15 (75.0) 3 (15.0) 2 (10.0) 10 (66.7) 5 (33.3) – 7 (53.8) 4 (30.8) 1 (7.7) -0.085 0.121 
Feeling that everything is an effort 9 (45.0) 10 (50.0) 1 (5.0) 9 (60.0) 5 (33.3) 1 (6.7) 5 (38.5) 6 (46.2) 2 (15.4) -0.242 0.161 
Feeling that life is not worth living 17 (85.0) 2 (10.0) 1 (5.0) 14 (93.3) 1 (6.7) – 10 (76.9) 2 (15.4) 1 (7.7) -0.248 0.344 
Thoughts about ending it all 18 (90.0) 1 (5.0) 1 (5.0) 14 (93.3) – 1 (6.7) 11 (84.6) 2 (15.4) – -0.040 0 
Effect of condition on sexual life 18 (90.0) 1 (5.0) 1 (5.0) 15 (100.0) – – 12 (92.3) 1 (7.7) – -0.040 0.164 
Religious/ 
spiritual 
Worrying thoughts about death or dying 13 (65.0) 6 (30.0) 1 (5.0) 9 (60.0) 5 (33.3) 1 (6.7) 8 (61.5) 4 (30.8) 1 (7.7) 0.026 0.118 
Religious or spiritual needs not being met 15 (75.0) 2 (10.0) 3 (15.0) 14 (93.3) 1 (6.7) – 12 (92.3) – 1 (7.7) -0.437 -0.225 
Independence Losing independence 14 (70.0) 4 (20.0) 2 (10.0) 11 (73.3) 4 (26.7) – 11 (84.6) 1 (7.7) 1 (7.7) -0.191 -0.249 
Changes in ability to carry out daily activities 14 (70.0) 5 (25.0) 1 (5.0) 10 (66.7) 4 (26.7) 1 (6.7) 10 (76.9) 2 (15.4) 1 (7.7) 0.085 -0.068 
Changes in ability to carry out household 
tasks 
13 (65.0) 6 (30.0) 1 (5.0) 10 (66.7) 5 (33.3) – 8 (61.5) 2 (15.4) 3 (23.1) -0.158 0.223 
Family/social Feeling that people do not understand what 
you want 
17 (85.0) 3 (15.0) – 11 (73.3) 4 (26.7) – 12 (92.3) 1 (7.7) – 0.327 -0.191 
Worrying about the effect illness is having 
on family/others 
4 (20.0) 9 (45.0) 7 (35.0) 3 (20.0) 7 (46.7) 5 (33.3) 4 (30.8) 7 (53.8) 2 (15.4) -0.174 -0.388 
Lack of support from family/others 18 (90.0) 1 (5.0) 1 (5.0) 14 (93.3) 1 (6.7) – 13 (100.0) – – -0.163 -0.306 
Needing more help than family/other can 
give 
19 (95.0) 1 (5.0) – 15 (100.0) – – 13 (100.0) – – -0.223 -0.223 
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Suppl. Table. Frequency distribution of individual needs and change-related effects sizes 
SPARC T1 (n=20) T2 (n=15) T3 (n=13) 
ES T1-T2 ES T1-T3 Domain 
of need 
Item 0 1 2-3 0 1 2-3 0 1 2-3 
Treatment 
concerns 
Side effects of treatment 8 (40.0) 7 (35.0) 5 (25.0) 5 (33.3) 9 (60.0) 1 (6.7) 8 (61.5) 4 (30.8) 1 (7.7) -0.186 -0.394 
Worry about long term effects of treatment 8 (40.0) 6 (30.0) 6 (30.0) 8 (53.3) 5 (33.3) 2 (13.3) 8 (61.5) 4 (30.8) 1 (7.7) -0.370 -0.518 
Abbreviations: ES – Effect size; SPARC – Sheffield Profile for Assessment and Referral to Care. 
Notes: Based on data after EM imputation; Key: Cohen’s d benchmarks d= 0.2 (small effect), 0.5 (moderate effect) and 0.8 (large effect); Key 2: ES of -0.25 indicates decrease of 0.25 SD 
 
